MK-3475 as Maintenance Therapy in Extensive Stage SCLC

NCT02359019 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Extensive Stage Small Cell Lung Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
OTHER: Laboratory Biomarker Analysis

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]